Rezolute, Inc. received positive news from the FDA, allowing them to resume US clinical trials for RZ358 (ersodetug), a potential treatment for hypoglycemia caused by congenital hyperinsulinism. This follows the FDA’s removal of partial clinical holds on the drug. The company anticipates enrollment of US participants in the global sunRIZE study to begin in early 2025.